Emmanuel Antonarakis, MD

GU Oncology Now

<p>Emmanuel Antonarakis, MD, of the Masonic Cancer Center at the University of Minnesota, discusses his study presented at ASCO GU 2024 on the use of PARP1 mRNA expression as a prognostic biomarker of aggressive disease and a predictor of response to PARP inhibition for patients with castration-sensitive prostate cancer.<p>He elaborates on the differences between PARP1 mRNA expression and other biomarkers currently used for risk stratification in this patient population, as well as how it can be used in the clinical decision-making process for patients.</p></p>


PARP1 mRNA Biomarkers in CSPC

mCSPC

Dr. Emmanuel Antonarakis discusses his study presented at ASCO GU 2024 on the use of PARP1 mRNA expression as a prognostic biomarker of aggressive disease.

About Us

Contributors and Partners

Editorial Policy

Advertising

eNewsletters

Calendar

Contact Us

Contribute

MashupMD

Cancer Nursing Today

Urban Health Today

Blood Cancers Today

DocWire News

Knowledge Hubs

Conference Coverage

Roundtables

The Uromigos

Uromigos Live 2024

AUC3

Localized

mHSPC/mCSPC

CRPC

Diagnostics

Prostate Cancer

Localized Renal Cell Carcinoma

Advanced Renal Cell Carcinoma

nccRCC

Renal Cell Carcinoma

Non-Muscle Invasive Urothelial Carcinoma

Muscle Invasive Urothelial Carcinoma

Advanced Urothelial Carcinoma

Upper Tract Urothelial Carcinoma

Urothelial Carcinoma

Testicular, Penile, and Rare Cancers

Video Insights

Advancements in Oncology

The Oncology Brothers

Expert Interviews

Journal

Subscribe